Jaen

• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin … Ended
  2024-513992-42-00 10 2022-09-13 venous thromboembolism (VTE) in patients with gastrointestinal/genitou
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on … Ended
  2023-509569-19-00 10 2022-08-10 venous thromboembolism (VTE)
• A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Admi … Ended
  2023-506380-33-00 5 2022-06-28 Early or Locally Advanced/ Inflammatory HER2-Positive Breast Cancer
• A clinical trial with nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer. … Ended
  2024-512052-38-00 9 2021-12-02 Advanced triple negative breast cancer
• The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic … Ended
  2024-517251-12-00 5 2021-11-02 Recurrent or metastatic head and neck squamous cell carcinoma
• A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participan … Ended
  2024-512227-36-00 9 2021-07-28 Advanced solid tumors
• Study of Atezolizumab plus chemotherapy plus chemo-radiotherapy and Atezolizumab maintenance therapy in non-resectable non-small cell lung c … Ended
  2024-514803-33-00 4 2021-06-16 Non-small cell lung cancer (NSCLC)
• European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial (SolidAct) Ended
  2022-500385-99-00 5 2021-06-03 SARS-CoV II infection (Coronavirus disease)
• A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab … Ended
  2023-507317-10-00 5 2021-05-10 Locally advanced, unresectable, or metastatic non small cell lung canc
• First time in human clinical test using a personalized tissue-engineered blood vessel to treat chronical illness in a vein. Ended
  2024-520148-40-00 1 2021-02-25 Chronic venous insufficiency
• TSRO-Ph2, Dostarlimab +CT vs Pembro +CT, 1L H2H efficacy comparison in Metastatic NSCLC pts. PERLA Ended
  2023-505894-33-00 4 2020-11-25 Lung Cancer, Non-Small Cell
• Pembrolizumab with Lenvatinib versus Docetaxel for Metastatic NSCLC after Platinum Doublet Chemotherapy and Immunotherapy Ended
  2022-501439-18-00 5 2019-06-26 NSCLC with squamous or nonsquamous histology
• Phase 3 Study of Pembrolizumab with or without Maintenance Olaparib in First-Line Metastatic Squamous NSCLC Ended
  2023-508449-41-00 5 2019-06-26 Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
• Clinical trial to compare the efficacy and tolerability of fulvestrant (FaslodexTM) 500mg with placebo versus fulvestrant (FaslodexTM) 500mg … Ended
  2024-516132-10-00 4 2016-02-05 Metastatic breast cancer

Showing 121–134 of 134 trials